Kang Byung Woog, Sohn Sang Kyun, Moon Joon Ho, Chae Yee Soo, Kim Jong Gwang, Lee Soo Jung, Kim Won Seog, Lee Je-Jung, Lee Se Ryeon, Park Keon Uk, Lee Ho Sup, Lee Won Sik, Won Jong-Ho, Park Moo-Rim, Kwak Jae-Yong, Kim Min Kyoung, Kim Hyo Jung, Oh Sung Yong, Kang Hye Jin, Suh Cheolwon
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Department of Hematology/Oncology, Internal Medicine, Samsung Medical Center, Seoul, Korea.
Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.
We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.
We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.
The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.
Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
我们调查了韩国套细胞淋巴瘤（MCL）患者的临床特征及治疗结果。
我们回顾性分析了2004年1月至2009年12月间在韩国15个医疗中心诊断为MCL的131例患者的临床特征及预后；所有患者均接受了至少1种针对MCL的化疗方案。
患者的中位年龄为63岁（范围26 - 78岁），77.9%为男性。共有105例患者（80.1%）在诊断时处于III期或IV期MCL。根据国际预后指数（IPI），52例患者（39.7%）被归类为高危或高中危MCL。根据简化的MCL-IPI（MIPI），18例患者（13.7%）属于高危组。结外受累的总体发生率为69.5%。诊断时骨髓和胃肠道受累的总体发生率分别为41.2%和35.1%。环磷酰胺、阿霉素、长春新碱、泼尼松龙和利妥昔单抗经常被用作一线治疗（41.2%）。中位随访时间为20.0个月（范围0.2 - 77.0个月），2年总生存率（OS）为64.7%，无事件生存率（EFS）为39.7%。多变量分析显示简化的MIPI与OS显著相关。然而，含利妥昔单抗方案的使用与OS和EFS无关。
与西方国家的结果相似，本研究发现简化的MIPI是韩国MCL患者的一个重要预后因素。
